-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 25, AbbVie/Allergan announced that it had submitted a new drug listing application (NDA) for AGN-190584 (1.
Presbyopia is a common progressive eye disease that reduces the ability of the eyes to focus on close objects and usually affects people over 40 years old.
AbbVie's application is mainly based on the results of two phase III studies code-named GEMINI 1 and GEMINI 2.
AGN-190584 is an improved new drug formulation of pilocarpine (a cholinergic muscarinic receptor agonist), which was developed as a once-daily eye drop for the treatment of presbyopia.
According to 1399 questionnaire surveys of middle-aged people aged 40-55 in the United States, 90% of the population suffers from presbyopia.
At present, there is no approved drug for presbyopia in the world, and there are currently 3 drugs in phase III research.